Search

Your search keyword '"Razavi-Shearer, Devin"' showing total 28 results
Start Over Author "Razavi-Shearer, Devin" Search Limiters Academic (Peer-Reviewed) Journals
28 results on '"Razavi-Shearer, Devin"'

2. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie

Published
2023
Full Text
View/download PDF

3. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

Author

Razavi, Homie A., Buti, Maria, Terrault, Norah A., Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S., Al Masri, Nasser M., Alalwan, Abduljaleel M., Aleman, Soo, Alghamdi, Abdullah S., Alghamdi, Saad, Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Altraif, Ibrahim H., Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J., Blach, Sarah, Braga, Wornei S.M., Brandão-Mello, Carlos E., Brunetto, Maurizia R., Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S., Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G., Ferreira, Paulo R.A., Forns, Xavier, Foster, Graham R., Gaeta, Giovanni B., Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S., Gholam, Pierre M., Gish, Robert G., Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D.E., Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A., Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V., Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J., Navas, Maria-Cristina, Naveira, Marcelo C.M., Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q., Pessoa, Mário G., Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M., Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y., Rodríguez, Manuel, Rosenberg, William M.C., Roulot, Dominique M., Ryder, Stephen D., Safadi, Rifaat, Sanai, Faisal M., Santantonio, Teresa A., Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L., Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S., Yang, Hwai-I, Yu, Ming-Lung, and Zuckerman, Eli

Published
2023
Full Text
View/download PDF

4. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Author

Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A

Published
2022
Full Text
View/download PDF

7. The economic argument for hepatitis B treatment simplification and expansion.

Author

Razavi‐Shearer, Devin

Abstract

One component of decisions regarding hepatitis B virus (HBV) treatment simplification and expansion is the economic perspective. Literature was reviewed for studies which provide estimates for the economic impact of simplifying and expanding treatment eligibility. Eight published studies and four unpublished studies were included and all but one subset of one study found that expanding treatment criteria would result in programs that would be at minimum cost‐effective and most often highly cost‐effective. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Nguyen, Mindie H, Chen, Ding-Shinn, Van Damme, Pierre, Abbas, Zaigham, Abdulla, Maheeba, Abou Rached, Antoine, Adda, Danjuma, Aho, Inka, Akarca, Ulus, Hasan, Fuad, Al Lawati, Faryal, Al Naamani, Khalid, Al-Ashgar, Hamad Ibrahim, Alavian, Seyed M, Alawadhi, Sameer, Albillos, Agustin, Al-Busafi, Said A, Aleman, Soo, Alfaleh, Faleh Z, Aljumah, Abdulrahman A, Anand, Anil C, Anh, Nguyen Thu, Arends, Joop E, Arkkila, Perttu, Athanasakis, Kostas, Bane, Abate, Ben-Ari, Ziv, Berg, Thomas, Bizri, Abdul R, Blach, Sarah, Brandão Mello, Carlos E, Brandon, Samantha M, Bright, Bisi, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Chan, Henry L Y, Chaudhry, Asad, Chien, Rong-Nan, Choi, Moon S, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Clausen, Mette R, Colombo, Massimo, Cornberg, Markus, Cowie, Benjamin, Craxi, Antonio, Croes, Esther A, Cuellar, Diego Alberto, Cunningham, Chris, Desalegn, Hailemichael, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve S, El-Sayed, Manal H, Estes, Chris, Falconer, Karolin, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gaeta, Giovanni B, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Goldis, Adrian, Gountas, Ilias, Gray, Richard, Guimarães Pessôa, Mário, Hajarizadeh, Behzad, Hatzakis, Angelos, Hézode, Christophe, Himatt, Sayed M, Hoepelman, Andy, Hrstic, Irena, Hui, Yee-Tak T, Husa, Petr, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jaroszewicz, Jerzy, Kaymakoglu, Sabahattin, Kershenobich, David, Kondili, Loreta A, Konysbekova, Aliya, Krajden, Mel, Kristian, Pavol, Laleman, Wim, Lao, Wai-cheung C, Layden, Jen, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Liakina, Valentina, Lim, Young-Suk S, Loo, Ching-kong K, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham O, Mamatkulov, Adkhamjon, Manns, Michael, Marinho, Rui T, Maticic, Mojca, Mauss, Stefan, Memon, Muhammad S, Mendes Correa, Maria C, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Mokhbat, Jacques E, Moreno, Christophe, Mossong, Joel, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Musabaev, Erkin, Nawaz, Arif, Nde, Helen M, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Njouom, Richard, Ntagirabiri, Renovat, Nurmatov, Zuridin, Obekpa, Solomon, Ocama, Ponsiano, Oguche, Stephen, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Opio, Christopher K, Örmeci, Necati, Papatheodoridis, George, Pasini, Ken, Pimenov, Nikolay, Poustchi, Hossein, Quang, Trân D, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Rios, Cielo Yaneth, Rjaskova, Gabriela, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Scott, Julia, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shiha, Gamal E, Shin, Tesia, Sievert, William, Sperl, Jan, Stärkel, Peter, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek S, Tanaka, Junko, Tomasiewicz, Krzysztof, Urbanek, Petr, van der Meer, Adriaan J, Van Vlierberghe, Hans, Vella, Stefano, Vince, Adriana, Waheed, Yasir, Waked, Imam, Walsh, Nicholas, Weis, Nina, Wong, Vincent W, Woodring, Joseph, Yaghi, Cesar, Yang, Hwai-I, Yang, Chung-Lin, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yusuf, Muhammed Aasim M, Zeuzem, Stefan, and Razavi, Homie

Published
2018
Full Text
View/download PDF

10. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Author

Razavi, Homie, Robbins, Sarah, Zeuzem, Stefan, Negro, Francesco, Buti, Maria, Duberg, Ann-Sofi, Roudot-Thoraval, Françoise, Craxi, Antonio, Manns, Michael, Marinho, Rui T, Hunyady, Bela, Colombo, Massimo, Aleman, Soo, Antonov, Krasimir, Arkkila, Perttu, Athanasakis, Kostas, Blach, Sarah, Blachier, Martin, Blasco, Antonio J, Calinas, Filipe, Calleja, Jose L, Christensen, Peer B, Cramp, Matthew E, Croes, Esther, de Knegt, Robert J, de Ledinghen, Victor, Delile, Jean-Michel, Estes, Chris, Falconer, Karolin, Färkkilä, Martti, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Gheorghe, Liana, Goldis, Adrian, Gountas, Ilias, Gregorčič, Sergeja, Gschwantler, Michael, Gunter, Jessie, Halota, Waldemar, Harcouet, Laura, Hézode, Christophe, Hoffmann, Patrick, Horvath, Gabor, Hrstic, Irena, Jarčuška, Peter, Jelev, Deian, Jeruma, Agita, Kåberg, Martin, Kieran, Jennifer, Kondili, Loreta A, Kotzev, Iskren, Krarup, Henrik, Kristian, Pavol, Lagging, Martin, Laleman, Wim, Lázaro, Pablo, Liakina, Valentina, Lukšić, Boris, Maimets, Matti, Makara, Mihály, Mateva, Lyudmila, Maticic, Mojca, Mennini, Francesco S, Mitova, Rumiana, Moreno, Christophe, Mossong, Joel, Murphy, Kimberly, Nde, Helen, Nemecek, Vratislav, Nonkovic, Dijana, Norris, Suzanne, Oltman, Marian, Øvrehus, Anne L H, Papatheodoridis, George, Pasini, Ken, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Reesink, Henk W, Reic, Tatjana, Rozentale, Baiba, Ryder, Stephen D, Salupere, Riina, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Simojoki, Kaarlo, Simonova, Marietta, Smit, Peter J, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Struck, Daniel, Sypsa, Vana, Thornton, Lelia, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van de Vijver, David, van der Meer, Adriaan J, van Santen, Daniela, Van Vlierberghe, Hans, Vandijck, Dominique, Vella, Stefano, Videčnik-Zorman, Jerneja, Vogel, Wolfgang, Weis, Nina, and Hatzakis, Angelos

Published
2017
Full Text
View/download PDF

11. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Author

Blach, Sarah, Zeuzem, Stefan, Manns, Michael, Altraif, Ibrahim, Duberg, Ann-Sofi, Muljono, David H, Waked, Imam, Alavian, Seyed M, Lee, Mei-Hsuan, Negro, Francesco, Abaalkhail, Faisal, Abdou, Ahmed, Abdulla, Maheeba, Rached, Antoine Abou, Aho, Inka, Akarca, Ulus, Al Ghazzawi, Imad, Al Kaabi, Saad, Al Lawati, Faryal, Al Namaani, Khalid, Al Serkal, Youssif, Al-Busafi, Said A, Al-Dabal, Layla, Aleman, Soo, Alghamdi, Abdullah S, Aljumah, Abdulrahman A, Al-Romaihi, Hamad E, Andersson, Monique I, Arendt, Vic, Arkkila, Perttu, Assiri, Abdullah M, Baatarkhuu, Oidov, Bane, Abate, Ben-Ari, Ziv, Bergin, Colm, Bessone, Fernando, Bihl, Florian, Bizri, Abdul R, Blachier, Martin, Blasco, Antonio J, Mello, Carlos E Brandão, Bruggmann, Philip, Brunton, Cheryl R, Calinas, Filipe, Chan, Henry L Y, Chaudhry, Asad, Cheinquer, Hugo, Chen, Chien-Jen, Chien, Rong-Nan, Choi, Moon Seok, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Clausen, Mette R, Cramp, Matthew E, Craxi, Antonio, Croes, Esther A, Dalgard, Olav, Daruich, Jorge R, de Ledinghen, Victor, Dore, Gregory J, El-Sayed, Manal H, Ergör, Gul, Esmat, Gamal, Estes, Chris, Falconer, Karolin, Farag, Elmoubashar, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, Gane, Ed, García-Samaniego, Javier, Khan, Amir Ghafoor, Gountas, Ilias, Goldis, Adrian, Gottfredsson, Magnús, Grebely, Jason, Gschwantler, Michael, Pessôa, Mário Guimarães, Gunter, Jessie, Hajarizadeh, Behzad, Hajelssedig, Omer, Hamid, Saeed, Hamoudi, Waseem, Hatzakis, Angelos, Himatt, Sayed M, Hofer, Harald, Hrstic, Irena, Hui, Yee-Tak, Hunyady, Bela, Idilman, Ramazan, Jafri, Wasim, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jeruma, Agita, Jonasson, Jón G, Kamel, Yasser, Kao, Jia-Horng, Kaymakoglu, Sabahattin, Kershenobich, David, Khamis, Jawad, Kim, Young S, Kondili, Loreta, Koutoubi, Zaher, Krajden, Mel, Krarup, Henrik, Lai, Moon-sing, Laleman, Wim, Lao, Wai-cheung, Lavanchy, Daniel, Lázaro, Pablo, Leleu, Henri, Lesi, Olufunmilayo, Lesmana, Laurentius A, Li, Michael, Liakina, Valentina, Lim, Young-Suk, Luksic, Boris, Mahomed, Adam, Maimets, Matti, Makara, Mihály, Malu, Abraham O, Marinho, Rui T, Marotta, Paul, Mauss, Stefan, Memon, Muhammad S, Correa, Maria C Mendes, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Moreno, Christophe, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Nde, Helen, Njouom, Richard, Nonkovic, Diana, Norris, Suzanne, Obekpa, Solomon, Oguche, Stephen, Olafsson, Sigurður, Oltman, Marian, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Øvrehus, Anne L H, Owusu-Ofori, Shirley, Oyunsuren, Tsendsuren S, Papatheodoridis, George, Pasini, Ken, Peltekian, Kevork M, Phillips, Richard O, Pimenov, Nikolay, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Ridruejo, Ezequiel, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Rosenberg, William M, Roudot-Thoraval, Françoise, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Avila, Juan F Sanchez, Saraswat, Vivek, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shevaldin, Anatoly, Shiha, Gamal E, Sievert, William, Sonderup, Mark, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Stauber, Rudolf E, Stedman, Catherine, Struck, Daniel, Su, Tung-Hung, Sypsa, Vana, Tan, Soek-Siam, Tanaka, Junko, Thompson, Alexander J, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van der Meer, Adriaan J, van Thiel, Ingo, Van Vlierberghe, Hans, Vince, Adriana, Vogel, Wolfgang, Wedemeyer, Heiner, Weis, Nina, Wong, Vincent WS, Yaghi, Cesar, Yosry, Ayman, Yuen, Man-fung, Yunihastuti, Evy, Yusuf, Aasim, Zuckerman, Eli, and Razavi, Homie

Published
2017
Full Text
View/download PDF

12. Cost‐effectiveness of treating all hepatitis B–positive individuals in the United States.

Author

Razavi‐Shearer, Devin, Estes, Chris, Gamkrelidze, Ivane, and Razavi, Homie

Subjects
*HEPATITIS B virus, *HEPATITIS, *ECONOMIC impact of disease, *CHRONIC hepatitis B, *HEPATITIS B, *COST effectiveness, *PRICE levels
Abstract

Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most of the infected individuals in the United States remain undiagnosed and untreated. There is a need to understand more completely the economic and disease burden impact of removing treatment restrictions and increasing diagnosis and treatment. The PRoGReSs model, a dynamic HBV model that tracks the infected population by year, disease stage, and gender, was used to quantify the disease and economic burden of chronic HBV infection in the United States from 2020 to 2050 based on four scenarios: a status quo (base) scenario and three treat‐all scenarios, in which screening, diagnosis, and treatment were maximized at different annual treatment price levels of $5382, $2000 and $750. Compared to the base scenario, the treat‐all scenarios would avert 71,100 acute and 11,100 chronic incident cases of HBV, and 169,000 liver‐related deaths from 2020 to 2050. At an annual treatment cost of $2000, treating all HBV infections would be highly cost‐effective, and at $750 would be cost saving and would achieve a positive return on investment before 2050. Maximizing the diagnosed and treated HBV population in the United States would avert a significant number of cases of advanced liver disease and related mortality. Such interventions can also be cost‐effective compared to the status quo strategy, and cost saving at a treatment price threshold of $750 annually, above the current lowest annual treatment cost of $362. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050.

Author

Biondi, Mia J., Estes, Chris, Razavi-Shearer, Devin, Sahdra, Kanwar, Lipton, Nechama, Shah, Hemant, Capraru, Camelia, Janssen, Harry L.A., Razavi, Homie, and Feld, Jordan J.

Subjects
HEPATITIS B vaccines, HEPATITIS B virus, INFANTS, HEPATITIS B, COST effectiveness
Abstract

Background: The World Health Organization recommends universal birth dose vaccination for hepatitis B virus (HBV), yet only 3 provinces and territories in Canada provide birth dose vaccination, and Canadian-born children in Ontario are acquiring HBV before adolescent vaccination. We sought to determine whether birth and/or infant HBV vaccination is cost-effective. Methods: We used a dynamic HBV model that incorporates population by year, disease stage, sex and the influence of immigration to quantify the disease and economic burden of chronic HBV infection in Ontario from 2020 to 2050. We compared 4 vaccination scenarios, which included a birth dose vaccine and variations of the 2 subsequent doses (either alone or as a part of the hexavalent vaccine) and a hexavalent-only strategy in infancy with the current adolescent vaccination strategy. Our costing estimates were based on values from 2020. Results: All 4 infant vaccination approaches prevented an additional 550–560 acute and 160 chronic pediatric HBV infections from 2020 to 2050 compared with adolescent vaccination. Whereas birth dose could be cost-effective, incorporating vaccination into a hexavalent vaccine was cost saving. By 2050, the hexavalent approach led to $428 000 in cost savings per disability-adjusted life years averted. Interpretation: At the current prevalence in Ontario, a switch to birth dose or infant dose will be cost-effective or even cost saving. Introducing any form of infant HBV immunization in Ontario will prevent acute and chronic pediatric HBV infections. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Now is the Time to Scale Up Birth-Dose Hepatitis B Vaccine in Low- and Middle-Income Countries.

Author

Thompson, Peyton, Parr, Jonathan B, Boisson, Alix, Razavi-Shearer, Devin, Ezechi, Oliver C, Wang, Su H, and Tucker, Joseph D

Subjects
HEPATITIS B vaccines, MIDDLE-income countries, LIVER cancer
Abstract

Fewer than half of the world's infants have access to the birth dose of hepatitis B vaccine (HBV), which prevents mother-to-child transmission of HBV and subsequent liver cancer. Now is the time to expand access for infants born in low-resource settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting.

Author

Linh-Vi Le, Blach, Sarah, Rewari, Bharat, Polin Chan, Cui Fuqiang, Naoko Ishikawa, Sharma, Mukta, Mangadan-Konath, Nabeel, Razavi, Homie, Low-Beer, Daniel, and Razavi-Shearer, Devin

Subjects
VIRAL hepatitis, HEPATITIS B, HEPATOCELLULAR carcinoma, HEPATITIS B virus, NATIONAL interest
Abstract

In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the region's progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, and HCV prevalence declined from 0.64% to 0.58%. The region achieved the 2020 target of 30% incidence reduction for HBV, whereas HCV incidence declined by 6%. Hepatocellular carcinoma incidence for HBV and HCV increased by 9% and 7%, respectively. Liver-related deaths from HBV rose by 8%, and mortality attributable to HCV plateaued. Large testing and treatment gaps remained in 2019: only 13% of chronic HBV infections were diagnosed and 25% treated; 21% of chronic HCV infection were diagnosed and 11% treated. Viral hepatitis must become national priority with adequate funding to reach elimination goals by 2030. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis.

Author

Lim, Young‐Suk, Ahn, Sang Hoon, Shim, Jae‐Jun, Razavi, Homie, Razavi‐Shearer, Devin, and Sinn, Dong Hyun

Subjects
ECONOMIC impact analysis, ECONOMIC models, HEPATITIS B virus, ALANINE aminotransferase, CHRONIC hepatitis B, HEPATOCELLULAR carcinoma, HEPATITIS B
Abstract

Summary: Background: Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients receive antiviral treatment globally. The complexity and strictness of the current clinical practice guidelines may limit expanding the treatment coverage for CHB. Aims: To examine the impact of expanding treatment criteria on future disease burden in Korea, a hepatitis B virus (HBV) endemic country with high diagnostic rates. Materials: Dynamic country‐level data were used to estimate the HCC incidence, overall mortality and economic impact of three incremental scenarios compared to the base case in Korea through 2035. Results: In 2020, 1,409,000 CHB cases were estimated, with the majority born before 1995. All scenarios assumed treating 70% of eligible individuals. The first scenario removed viral load restrictions in cirrhotic patients, which would avert 13,000 cases of HCC and save 11,800 lives. The second scenario, lowering the alanine aminotransferase (ALT) level restriction to the upper limit of the normal in non‐cirrhotic patients, would avert 26,700 cases of HCC and save 23,300 lives. The last scenario removed the restriction by ALT and HBeAg in treating non‐cirrhotic individuals with a viral load of ≥2000 IU/ml, which would avert 43,300 cases of HCC and save 37,000 lives. All scenarios were highly cost‐effective. Conclusions: Simplifying and expanding treatment eligibility for CHB would save many lives and be highly cost‐effective when combined with high diagnostic rates. These dynamic country‐level data may provide new insights for their global application. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting.

Author

Le, Linh‐Vi, Blach, Sarah, Rewari, Bharat, Chan, Polin, Fuqiang, Cui, Ishikawa, Naoko, Sharma, Mukta, Mangadan‐Konath, Nabeel, Razavi, Homie, Low‐Beer, Daniel, and Razavi‐Shearer, Devin

Subjects
VIRAL hepatitis, HEPATITIS B, HEPATOCELLULAR carcinoma, HEPATITIS B virus, NATIONAL interest
Abstract

In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016‐2021. We examine the region's progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, and HCV prevalence declined from 0.64% to 0.58%. The region achieved the 2020 target of 30% incidence reduction for HBV, whereas HCV incidence declined by 6%. Hepatocellular carcinoma incidence for HBV and HCV increased by 9% and 7%, respectively. Liver‐related deaths from HBV rose by 8%, and mortality attributable to HCV plateaued. Large testing and treatment gaps remained in 2019: only 13% of chronic HBV infections were diagnosed and 25% treated; 21% of chronic HCV infection were diagnosed and 11% treated. Viral hepatitis must become national priority with adequate funding to reach elimination goals by 2030. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19.

Author

Blach, Sarah, Blomé, Marianne, Duberg, Ann‐Sofi, Jerkeman, Anna, Kåberg, Martin, Klasa, Per‐Erik, Lagging, Martin, Razavi‐Shearer, Devin, Razavi, Homie, and Aleman, Soo

Subjects
COVID-19, COVID-19 pandemic, HEPATITIS C virus, HARM reduction, HEPATITIS C, INFECTIOUS disease transmission
Abstract

Background & Aims: In 2014, the burden of hepatitis C virus (HCV) in Sweden was evaluated, to establish a baseline and inform public health interventions. Considering the changing landscape of HCV treatment, prevention, and care, and in light of the COVID‐19 pandemic, this analysis seeks to evaluate Sweden's progress towards the World Health Organization (WHO) elimination targets and identify remaining barriers. Methods: The data used for modelling HCV transmission and disease burden in Sweden were obtained through literature review, unpublished sources and expert input. A dynamic Markov model was employed to forecast population sizes and incidence of HCV through 2030. Two scenarios ('2019 Base' and 'WHO Targets') were developed to evaluate Sweden's progress towards HCV elimination. Results: At the beginning of 2019, there were 29 700 (95% uncertainty interval: 19 300‐33 700) viremic infections in Sweden. Under the base scenario, Sweden would achieve and exceed the WHO targets for diagnosis, treatment and liver‐related death. However, new infections would decrease by less than 10%, relative to 2015. Achieving all WHO targets by 2030 would require (i) expanding harm reduction programmes to reach more than 90% of people who inject drugs (PWID) and (ii) treating 90% of HCV + PWID engaged in harm reduction programmes and ≥7% of PWID not involved in harm reduction programmes, annually by 2025. Conclusions: It is of utmost importance that Sweden, and all countries, find sustainability in HCV programmes by broadening the setting and base of providers to provide stability and continuity of care during turbulent times. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Author

Razavi, Homie, Blach, Sarah, Razavi-Shearer, Devin, Abaalkhail, Faisal, Abbas, Zaigham, Abdallah, Ayat, Abrao Ferreira, Paulo, Abu Raddad, Laith Jamal, Adda, Danjuma, Agarwal, Kosh, Aghemo, Alessio, Ahmed, Aijaz, Al‐Busafi, Said A, Al‐hamoudi, Waleed, Al‐Kaabi, Saad, Al‐Romaihi, Hamad, Aljarallah, Badr, AlNaamani, Khalid, Alqahtani, Saleh, and Alswat, Khalid

Subjects
VIRAL hepatitis, HEPATITIS C virus, HEPATITIS B virus, MOTIVATION (Psychology), EXPECTATION (Psychology), MORTALITY
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries' progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1‐year‐olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year‐to‐year decrease in new HCV‐ and HBV‐related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models.

Author

de Villiers, Margaret J., Gamkrelidze, Ivane, Hallett, Timothy B., Nayagam, Shevanthi, Razavi, Homie, and Razavi-Shearer, Devin

Subjects
HEPATITIS B virus, VIRUS diseases, HEPATITIS B vaccines, VACCINES, SIMULATION methods & models, HEPATITIS B
Abstract

Hepatitis B is a global epidemic that requires carefully orchestrated vaccination initiatives in geographical regions of medium to high endemicity to reach the World Health Organization's elimination targets by 2030. This study compares two widely-used deterministic hepatitis B models—the Imperial HBV model and the CDA Foundation's PRoGReSs—based on their predicted outcomes in four countries. The impact of scaling up of the timely birth dose of the hepatitis B vaccine is also investigated. The two models predicted largely similar outcomes for the impact of vaccination programmes on the projected numbers of new cases and deaths under high levels of the infant hepatitis B vaccine series. However, scenarios for the scaling up of the infant hepatitis B vaccine series had a larger impact in the PRoGReSs model than in the Imperial model due to the infant vaccine series directly leading to the reduction of perinatal transmission in the PRoGReSs model, but not in the Imperial model. Meanwhile, scaling up of the timely birth dose vaccine had a greater impact on the outcomes of the Imperial hepatitis B model than in the PRoGReSs model due to the greater protection that the birth dose vaccine confers to infants in the Imperial model compared to the PRoGReSs model. These differences underlie the differences in projections made by the models under some circumstances. Both sets of assumptions are consistent with available data and reveal a structural uncertainty that was not apparent in either model in isolation. Those relying on projections from models should consider outputs from both models and this analysis provides further evidence of the benefits of systematic model comparison for enhancing modelling analyses. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.

Author

Hajarizadeh, Behzad, Razavi-Shearer, Devin, Merat, Shahin, Alavian, Seyed Moayed, Malekzadeh, Reza, and Razavi, Homie

Subjects
*HEPATITIS C diagnosis, *HEPATITIS C prevention, *HEPATITIS C treatment, *ANTIVIRAL agents, *HEPATITIS C, *HEPATOCELLULAR carcinoma, *INTERFERONS, *CIRRHOSIS of the liver, *DISEASE prevalence, *LIVER diseases, *DISEASE progression, *DESCRIPTIVE statistics, *DISEASE risk factors
Abstract

Background: Chronic hepatitis C virus (HCV) infection is emerging as the leading cause of viral hepatitis-related liver disease in Iran. Objectives: This study estimated the current and future disease burden of HCV infection in Iran and assessed the impact of various strategies in access to HCV treatment on reducing the disease burden. Materials and Methods: A modeling approach was used to estimate the size of HCV infected population, and disease progression from 2014 to 2030. Literature review and expert consensus informed the model parameters. Base case scenario assumed the currently utilized Interferon (IFN)-based treatment. Five other scenarios assumed utilizing IFN-free direct acting anti-viral regimens with 1, the base case diagnosis and treatment uptake; 2, restricting treatment to severe liver fibrosis; 3, treatment uptake being doubled; 4, stepwise increase in treatment uptake (doubled by 2017, quadrupled thereafter); 5, targeting at least 90% reduction in HCV infections by 2030. Results: In 2014, an estimated 186,500 individuals are living with HCV infection in Iran (median age: 30 years). By 2030, this number will increase to 213,700, while three to four fold increase is expected in the case numbers of decompensated cirrhosis (DC, n = 620), hepatocellular carcinoma (HCC, n = 510), and liver disease death (n = 400), assuming the current diagnosis/treatment settings. As compared with the base case scenario, scenarios 1 and 2 will have a limited impact on HCV disease burden, while scenarios 3 and 4 will result in 45% - 49% decrease in the number of individuals living with HCV infection and 60% - 69% decrease in DC, HCC and liver disease deaths by 2030. For at least 90% reduction in HCV infections by 2030 (scenario 5), diagnosis and treatment rates should be increased to 12,000 and 9,000 individuals per year in 2016, respectively and to 24,000 and 18,000 individuals per year, respectively in 2018 onward. Conclusions: An increasing burden of HCV-related liver disease is expected in Iran under the current diagnosis and treatment levels. Increased diagnosis and treatment uptake is required in combination with enhanced treatment efficacy to reduce the HCV burden. The relatively young age of the HCV infected population, provides an opportunity for timely interventions to avert the projected rising HCV disease burden in Iran. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

25. Impact of COVID-19 on global HCV elimination efforts.

Author

Blach, Sarah, Kondili, Loreta A., Aghemo, Alessio, Cai, Zongzhen, Dugan, Ellen, Estes, Chris, Gamkrelidze, Ivane, Ma, Siya, Pawlotsky, Jean-Michel, Razavi-Shearer, Devin, Razavi, Homie, Waked, Imam, Zeuzem, Stefan, and Craxi, Antonio

Subjects
*COVID-19, *VIRAL hepatitis, *TREATMENT delay (Medicine), *MIDDLE class, *HIGH-income countries
Abstract

Coronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in HCV liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination programs. Previously developed models were adapted for 110 countries to include a status quo or 'no delay' scenario and a '1-year delay' scenario assuming significant disruption in interventions (screening, diagnosis, and treatment) in the year 2020. Annual country-level model outcomes were extracted, and weighted averages were used to calculate regional (WHO and World Bank Income Group) and global estimates from 2020 to 2030. The incremental annual change in outcomes was calculated by subtracting the 'no-delay' estimates from the '1-year delay' estimates. The '1-year delay' scenario resulted in 44,800 (95% uncertainty interval [UI]: 43,800–49,300) excess hepatocellular carcinoma cases and 72,300 (95% UI: 70,600–79,400) excess liver-related deaths, relative to the 'no-delay' scenario globally, from 2020 to 2030. Most missed treatments would be in lower-middle income countries, whereas most excess hepatocellular carcinoma and liver-related deaths would be among high-income countries. The impact of COVID-19 extends beyond the direct morbidity and mortality associated with exposure and infection. To mitigate the impact on viral hepatitis programming and reduce excess mortality from delayed treatment, policy makers should prioritize hepatitis programs as soon as it becomes safe to do so. COVID-19 has resulted in many hepatitis elimination programs slowing or stopping altogether. A 1-year delay in hepatitis diagnosis and treatment could result in an additional 44,800 liver cancers and 72,300 deaths from HCV globally by 2030. Countries have committed to hepatitis elimination by 2030, so attention should shift back to hepatitis programming as soon as it becomes appropriate to do so. • With only 10 years left to meet the WHO's hepatitis elimination targets, COVID-19 is impacting progress. • A 1-year delay in HCV programs could cause excess HCV morbidity and mortality. • A 1-year delay could cause 72,000 excess deaths from HCV. • Most excess deaths would be in the lower middle income and high-income groups. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.

Author

Fraňková, Soňa, Urbánek, Petr, Husa, Petr, Němeček, Vratislav, Razavi, Homie, Razavi-Shearer, Devin, Chlíbek, Roman, and Šperl, Jan

Subjects
*HEPATITIS, *DISEASES, *EXPERIMENTAL medicine, *CHRONIC hepatitis C, *THERAPEUTICS
Abstract

Objective: Chronic HCV infection is associated with cirrhosis of the liver, hepatocellular carcinoma (HCC), and liver transplantation. HCV disease burden and the impact of new potent direct acting antivirals (DAAs) in the Czech Republic are unknown.Methods: Using a modelling framework, HCV disease progression in the Czech Republic was predicted to 2030 under the current standard of care treatment structure. In addition, two strategies to reduce the future burden of HCV infection were modelled: an incremental increase in treatment annually and WHO targets.Results: The number of viremic infected individuals in the Czech Republic is estimated to peak in 2026 (n = 55,130) and to decline by 0.5% by 2030 (n = 54,840). The number of individuals with compensated cirrhosis (n = 1,400), decompensated cirrhosis (n = 80), HCC (n = 70), and liver-related deaths (n = 60) is estimated to more than double by 2030. Through aggressive increases in diagnosis and treatment, HCV related mortality may decrease by 70% by 2030.Conclusions: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results